Settlement yesterday is just the beginning for CRDF

{"summary": "Bullish CRDF thesis citing a litigation settlement, an analyst upgrade, insider buying, and an advancing Phase 3 oncology program.", "reason": "The author provides a fundamental catalyst (settlement of litigation) and insider activity to support a long thesis on CRDF.", "ideas": [{"symbol": "CRDF", "direction": "long", "thesis": "Cardiff Oncology's settlement with Nerviano (NMS) secures exclusive rights and extends royalties for onvansertib, removing the inventorship litigation the author says was the only thing holding the stock back. The drug is advancing to a global Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer targeting accelerated approval based on ORR, with Phase 3 targeted for Q1 2027. HC Wainwright upgraded CRDF to BUY with a $9 price target, and the author cites a roughly $1M insider purchase by Gary Pace at about a $1.50 cost average. Main risk implied is execution/timing of the Phase 3 program and the company's modest cash position (~$34.5M at Q2 2026 plus $10M raised in July 2026).", "thesis_short": "CRDF settlement clears path to Phase 3", "quote": "The settlement yesterday with NMS (Nerviano) secures exclusive rights and extends royalties for onvansertib, which is advancing to a global Phase 3 trial in first-line RAS mutated metastatic colorectal cancer.", "confidence": 0.8, "sentiment": 0.8, "timeframe": "Phase 3 targeted Q1 2027"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}